Member Info for Skippysb01

Good grief. I mean the absolute state of it. Really?

Groan. Drinks bleach. Cures the virus by dying before it can get you. Cause of death - idiot.

Darwin award soon?

For any other holding I would have an idea what SP I would sell at. This one is different. Holding until the sale is either announced or cancelled. To be clear I anticipate there will be a sale.

I'll assess then. There is just no way of knowing what the value of the dividend will be right now. I'll take a view on whether to hold my current shares based on what is not sold/what the company looks like after a sale. I could sell ahead of the ex div date.

There is a mother scenario where there is no material sale but the company goes into production with significant revenue potential... I doubt this will happen but it might and that might cause me to hold.

I have no idea!! It's that sort of share. From a risk reward perspective I have decided to hold until a material announcement on the sale - good or bad - whatever happens before then.

A2P3 progression will give us £2. SP shot to £1.9 when Castro 'inappropriately' called it a couple of months ago.

However if we get announcement that progression isn't happening..... well it would present a buying opportunity.

Once Sprinter P3 final dosing RNS comes in November then we get a steady rise of optimism in anticipation of results being published in Q122. This will be an exciting time for investors. I'm not ramping - there will also be news of other treatments as with Merck but still it will be an energising time.

Kiwi, Yup my partner occasionally gets a return of the breathlessness but each time is hasn't been as bad and I think she is waiting for a follow on appointment from the hospital. Anyways good luck with it.

In the kindest possible way we are all hoping you were on the placebo!

gje - For the USA Activ2 trial. We could be notified of progression or not to Activ3 any time now.

For SNG's own global trial expect to be notified of last patient dosed in November with results in Late Jan/Feb next year.

Kiwi. So sorry that you have had all this Covid stuff. Chin up chap I really hope you feel better soon. My other half got really sick at the start of the pandemic and at that time we couldn't verify for certain that she had Covid as the NHS folk just said she wasn't quite sick enough to be tested. Now it's fairly clear she did and still has some lung scarring (visible on an X-ray months later) and what she describes as twitchy eyes. Not as serious as you but it's scary stuff.

It's a pretty dreadful day across all markets so far today today. A day to drink tea, look away from the screen, read some Patrick O'Brien, dream of blue seas....

I have the radio on in the background whilst I'm working this morning. I wasn't really taking any notice but then I heard the words 'Type 1 Interferon' mentioned. This triggered me somewhat. They were talking about Covid toe!

It would be material enough that SNG should release it immediately they know (as is practicable). Unless news is outside of trading hours of course.

So any time now.

We used the word 'shortly' in a work context yesterday for something we couldn't be sure would be complete in the next few days but were confident it wouldn't be weeks. It can mean anything and is quite useful in that context. The RNS was carefully written and I take the meaning of 'shortly' to be that the report is in the latter stages of review and sign off. Review and sign off can be quick or there can be iterations that require further work. Hence the board not being too specific.

Unfortunately for us it remains a case of 'any day now tomorrow'.

But it won't be long...

Zwartkps. Making it up as you go along now.

'Extinct covid test'. Just utter lies.

In the bin with you.

Significant and substantial kipper size.

TLWilliams. Precisely and well put.

Stu. I disagree that the company is prepared to discuss the Sprinter trial in detail. Only details presented are likely timetable (they own the trial) and details further interpreted from earlier trials..... nothing else. But in any case they can discuss this more openly because they own the trial. They do not own the Activ trial so details from SNG are minimal for the reasons I suggested.

I also do not agree that there is a morphing towards from Covid to general serious respiratory. This has always been the direction. Covid generates interest and potential for a revenue opportunity but SNG have been working on this for way longer than Covid has been around.

Your trading strategy makes some sense though. Dependent on Active 2 I can see a peak followed by a trough followed by a very large spike. Speculative I know. It's not for me. I hovered over selling half before the Interim results and explained my concern on here. The fact I didnt do it tells me trading is not for me..... but if the SP hits 190+ again on Activ2 progression (it idd on rumour of progression) then I will go through the same angst...

I'm not sure on the adaptive nature of the Activity trial other that to note that a lot of money has gone into finding a range of solutions to what is still a massive problem in the US. To my mind they would need a reason not to progress it considering SNG own earlier trial results - especially considering it's safety profile.

It's been a predictable fall. PI's leaving ship based on fear. I get it. It's hard to hold long term and actually it takes practice. BUT I see no evidence of intuitional selling whatsoever. If we get an RNS that says something different well let's see.

The market does not like 'updates'. It dislikes delays even more. But has the outcome post P3 trial results actually changed? For me it hasn't. I can assume there will be competition, I can assume that the pandemic may or may not be more or less prevalent.... All + or - the overall SP multiplier on the outcomes.

If the trials show even half the efficacy of the earlier trials this has to fly. Nobody does'nt need an effective solution to people dying in there scores in hospital.

Ive been looking at the Interim Results paper this morning and reflecting on the views being expressed here. This is the content from the Interim Report:

'This US National Institute of Health (NIH) Phase II/III ACTIV-2 study is led by the NIAID-funded AIDS Clinical Trials Group (ACTG). The trial is an adaptive, randomised, blinded, placebo- controlled trial which involved treating 110 patients with SNG001 in a home-based setting. Phase II is now completed, and a review is underway to determine whether SNG001 should be advanced into the Phase III part of the trial.'

Some are suggesting that SNG are not interested in this and that RM is downplaying it because we now know that SNG is more effective for more breathless patients. Perhaps the latter point is more likely a factor in SNG's thinking but I do not believe they have any visibility of what is going on in Activ2.

I suggest the reason there is no more on this in the Interim Results is down to RM not having any visibility of the trial data and that making assumptions about how it's going is a commercially sensitive area that cannot be covered in the Interim Report. If he says it's going well or badly without any visibility of what is going on inside the trial he is just looking for trouble when the results are released.

Also. With just 120 patients in Activ2 it means that that on it's own would not be enough to progress to EUA. SNG know this and therefore have outlined the strategy of waiting for P3 results which are far more material.

Just my thoughts as I see folks wavering and this caused me to dig a little to see if I could find any real data to support that. . We make our own investment decisions but I somehow feel that some of the downplaying of Activ2 is based on uncertainty rather than any actual facts. One person here actually stated that RM had said he's not interested in Activ2 outcomes. He did not.

GLA

Who said SNG do not want to participate in Activ3?

SNG have provided an update based around the trials and strategy that they manage themselves. If they progress on the USA trial they will talk about it then but until that does happen or they are dropped SNG has no information to share.

It may be that RM has somewhat limited expectations by showing us at what stage of the infection SNG is likely to benefit patients but if anyone was certain it would not progress it would have been dropped already. So there is data to review still.

They got the outcome they wanted and probably bought in on Friday looking to sell again on the next rise. They will then be back to deramp at the first opportunity. Whether or not they actually make any difference is a moot point as the SP was bound to fall on news of more time required for trials.

Won’t matter if P3 trials show efficacy. Good time to top up if you can mind.

NDAs will stay in place until after material news is made public. We won’t here anything in detail about a sale until a formal offer has been received.